Choosing which treatment regimen to prescribe a person living with hepatitis C depends on that patient's medical history, HCV genotype, level of liver damage and coinfections. For treatment-naive patients with genotype 1 (the most common genotype) and no liver damage, the AASLD/IDSA guidelines currently recommend:
- Elbasvir/Grazoprevir (Zepatier)
- Ledipasvir/Sofosbuvir (Harvoni)
Paritaprevir/Ritonavir (Viekira Pak)
- Sofosbuvir (Sovaldi) + Daclatasvir (Daklinza)
- Sofosbuvir (Sovaldi) + Simeprevir (Olysio)
For a detailed description of treatment recommendations for more complex patient populations, please refer to the full AASLD/IDSA guidelines, which are updated on a continual basis.
Lucinda K. Porter, R.N.
Mark Sulkowski, M.D.
Paul E. Sax, M.D.
Hamish Innes, David Goldberg and Sharon Hutchinson